Eiger Bio strengthens senior management team

Published: 26-May-2016
Pharmaceutical

By hiring Debra Odink as Senior Vice President of Technical Operations


Eiger BioPharmaceuticals, a US biopharmaceutical company located in Palo Alto, California which is focused on the development of targeted therapies for orphan diseases, says Debra Odink has joined the firm as Senior Vice President of Technical Operations.

Most recently, Dr Odink was Chief Technical Officer and Senior Vice President at Anthera Pharmaceuticals. Previously, she was Vice President of Pharmaceutical Chemistry and Product Development at Peninsula Pharmaceuticals, acquired by Johnson and Johnson in 2005. She began her career in industry at Roche including positions as Principal Research Scientist and CMC Leader.

  • Companies:
  • Eiger BioPharmaceuticals
See more

You may also like

Finance

Eiger BioPharmaceuticals closes merger with Celladon

Read more
The US firm is developing a clinical stage pipeline of orphan disease programmes

Trending Articles

  1. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  2. How pharma packaging manufacturers role is evolving: the case of extractables testing As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
  3. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Finance

Eiger BioPharmaceuticals closes merger with Celladon

The US firm is developing a clinical stage pipeline of orphan disease programmes
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Can creative carriers deliver the goods?

There are many reasons why conventional drug delivery technologies may not be effective and a more creative approach is required to convey the active ingredient to its destination. Dr Sarah Houlton looks at the more promising technologies in development
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now